Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Director departure
Quarterly results
|
|
TG THERAPEUTICS, INC. (TGTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/01/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/08/2022 |
8-K
| Quarterly results |
| 03/01/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/02/2021 |
8-K
| Quarterly results |
| 05/10/2021 |
8-K
| Quarterly results |
| 03/02/2021 |
8-K
| Quarterly results |
| 11/09/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 03/03/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/09/2019 |
8-K
| Quarterly results |
| 05/10/2019 |
8-K
| Quarterly results |
| 11/09/2018 |
8-K
| Quarterly results |
| 05/08/2018 |
8-K
| Quarterly results |
| 03/08/2018 |
8-K
| Quarterly results |
| 11/08/2017 |
8-K
| Quarterly results |
| 08/09/2017 |
8-K
| Quarterly results |
| 11/07/2016 |
8-K
| Quarterly results |
| 05/10/2016 |
8-K
| Quarterly results |
| 03/07/2016 |
8-K
| Form 8-K - Current report |
| 11/09/2015 |
8-K
| Quarterly results |
| 08/10/2015 |
8-K
| Quarterly results |
| 05/04/2015 |
8-K/A
| Quarterly results |
| 05/04/2015 |
8-K
| Quarterly results |
| 03/11/2015 |
8-K
| Quarterly results |
| 11/10/2014 |
8-K
| Quarterly results|
Docs:
|
"TG Therapeutics, Inc. Selected Consolidated Financial Data Statements of Operations Information : Three months ended September 30, Nine months ended September 30, 2014 2013 2014 2013 License revenue $ 38,096 $ 38,096 $ 114,286 $ 114,286 Costs and expenses: Research and development: Noncash stock expense associated with in-licensing agreements 4,138,844 — 5,350,094 — Noncash compensation 1,200,575 171,442 6,402,296 892,313 Other research and development 8,352,154 3,138,119 13,197,183 9,014,776 Total research and development 13,691,573 3,309,561 24,949,573 9,907,089 General and administrative: Noncash compensation 2,895,997 825,313 9,664,560 3,363,687 Other general and administrative 889,872 550,639 2,500,121 1,833,733 Total general and administrative 3,785,869 1,375,952 12,164,681 5,197,420..." |
|
| 07/21/2014 |
8-K
| Quarterly results|
Docs:
|
"TG Therapeutics, Inc. Selected Consolidated Financial Data Statements of Operations Information : Three months ended June 30, Six months ended June 30, 2014 2013 2014 2013 License revenue $ 38,095 $ 38,095 $ 76,190 $ 76,190 Costs and expenses: Research and development: Noncash stock expense associated with in-licensing agreement 1,211,250 — 1,211,250 — Noncash compensation 3,300,111 366,168 5,201,721 720,871 Other research and development 2,336,771 4,661,455 4,845,029 5,876,657 Total research and development 6,848,132 5,027,623 11,258,000 6,597,528 General and administrative: Noncash compensation 4,438,735 1,007,600 6,768,563 2,538,374 Other general and administrative 706,725 631,637 1,610,249 1,283,094 Total general and administrative 5,145,460 1,639,237 8,378,812 3,821,468 Total costs an..." |
|
| 05/12/2014 |
8-K
| Quarterly results|
Docs:
|
"TG Therapeutics, Inc. Selected Consolidated Financial Data Statements of Operations Information : Three Months Ended March 31, 2014 2013 License revenue $ 38,095 $ 38,095 Costs and expenses: Research and development: Noncash stock expense associated with in-licensing agreement -- -- Noncash compensation 1,901,610 354,703 Other research and development 2,508,258 1,215,202 Total research and development 4,409,868 1,569,905 General and administrative: Noncash compensation 2,329,828 1,530,774 Other general and administrative 903,524 651,457 Total general and administrative 3,233,352 2,182,231 Total costs and expenses 7,643,220 3,752,136 Operating loss Other expense: Interest income Other income -- Interest expense 226,340 231,472 Change in fair value of notes payable Total other expense Co..." |
|
| 03/05/2014 |
8-K
| Quarterly results|
Docs:
|
"TG Therapeutics, Inc. Selected Consolidated Financial Data Statements of Operations Information : Three Months Ended December 31, Year Ended December 31, 2013 2012 2013 2012 License revenue $ 38,095 $ 19,048 $ 152,381 $ 19,048 Costs and expenses: Research and development: Noncash stock expense associated with in-licensing agreement -- -- -- 16,578,000 Noncash compensation 149,206 219,520 1,041,519 455,809 Other research and development 3,606,385 860,222 12,621,161 3,994,182 Total research and development 3,755,591 1,079,742 13,662,680 21,027,991 General and administrative: Noncash compensation 797,942 1,024,072 4,161,629 2,966,373 Other general and administrative 662,728 501,123 2,496,461 1,815,083 Total general and administrative 1,460,670 1,525,195 6,658,090 4,781,456 Impairment of in-pr..." |
|
| 08/01/2013 |
8-K
| Form 8-K - Current report |
|
|
|